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Abstract
Background: Asymptomatic nasopharyngeal carriage represents an important biological marker for monitoring
pneumococcal serotype distribution and evaluating vaccine effects. Serotype determination by conventional
method (Quellung reaction) is technically and financially challenging. On the contrary, PCR-based serotyping
represents a simple, economic and promising alternative method.
Method: We designed a novel multiplex PCR assay for specific detection of the 30 classical colonizing S.
pneumoniae serogroups/types. This multiplex assay is composed of 7 consecutive PCR reactions and was validated
on a large and recent collection of Streptococcus pneumoniae isolated during a prospective study conducted in
Belgium at the time of PCV7 adoption.
Results: The multiplex PCR assay allowed the typing of more than 94% of the isolates of a collection of
pneumococci isolated from Belgian preschool attendees (n = 332). Seventy-five percent of the isolates were typed
after 3 subsequent PCR reactions. Results were in agreement with the Quellung identification.
Conclusion: Our novel multiplex assay is an accurate and reliable method which can be used in place of the
conventional method for S. pneumoniae carriage studies.
Background
S. pneumoniae is a major cause of morbidity and
mortality worldwide. The World Health Organisation
estimates that 1.6 million people among which 0.7 to 1
million children under 5 die of pneumococcal diseases
each year [1]. The nasopharynx of young children repre-
sents the ecological niche of S. pneumoniae as well as
the reservoir for pneumococcal transmission within the
community. Colonisation is also recognized as the first
step of disease development [2]. S. pneumoniae major
virulence factor is the capsular polysaccharide upon
which S. pneumoniae classification is based. Today, 93
different serotypes (including the recently discovered 6D
and 11E [3,4]), belonging to 46 serogroups, have been
described [5,6]. Serotypes differ by geographical preva-
lence [7], attack rate [8], age distribution [7] tendency to
cause outbreaks [9,10] and propensity to acquire antimi-
crobial resistance genes [11-13]. The capsular
polysaccharide is also the target of pneumococcal
vaccine. The currently available protein conjugate vac-
cine, PCV7, protects against 7 clinically-relevant sero-
types in young children (4, 6B, 9V, 14, 18C, 19F, 23F).
Because of its coverage limitation, it has induced repla-
cement of vaccine serotypes strains (VT) by non-vaccine
serotypes strains (NVT) in colonisation and subse-
quently in disease [14,15]. The long-term effects of a
vaccine targeting only a restricted number of serotypes
remain unknown. It is therefore crucial to keep ongoing
surveillance of pneumococcal serotypes in invasive dis-
eases [15,16] and in carriage [17-19].
Serotype determination relies on the Quellung reac-
tion. Binding of specific monoclonal antibodies with the
capsule induces a capsular swelling visualised under the
microscope. This technique remains the gold standard
for pneumococcal serotyping but presents major draw-
backs: high cost of antisera, technical expertise require-
ments and subjectivity in interpretation of results [20].
All these hindrances restrict S. pneumoniae serotyping
to a few reference laboratories [21].
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encoded by the cps (capsular polysaccharide synthesis)
locus. Sequencing of the cps locus of the 93 known
serotypes provided the molecular basis for PCR-based
serotyping developments [22]. A first sequential multi-
plex PCR assay specific to invasive pneumococcal dis-
eases (IPD) distribution in the USA was developed by Pai
and colleagues [23]. This initial assay was modified based
on IPD epidemiology encountered in different geographi-
cal areas (Brazil, Mozambique and Spain) [21,24,25]. It
was also successfully applied for S. pneumoniae serotypes
detection from nasopharyngeal (colonizing) and cerebro-
spinal fluid (IPD) samples [21,26-28] (Table 1). To con-
clude, most of the multiplex PCR assays developed so far
are specific to IPD strains. Only two studies (in the USA
and the Gambia) have used the IPD designed multiplex
PCR in carriage studies [28,29]. To optimize the rapid
detection of carriage-associated serotypes, we developed
a sequential multiplex PCR assay specific to colonizing
pneumococci. This assay was experimentally tested on a
collection of more than 300 pneumococci isolated in
Belgium and representing carriage serotypes distribution
in Europe. This new multiplex scheme successfully
identified 95% of the isolates.
Methods
Study design
We carried out a prospective cohort study on healthy
children (3-6 year-old) from 11 preschools of the Brus-
sels area between September 2006 and May 2008, time
of PCV7 introduction in Belgium [30]. Nasopharyngeal
aspirates were performed three times during the school
years on 333 children (mean age 4.2 years). A total of
8 3 0s a m p l e sw e r ea n a l y s e df o rt h ep r e s e n c eo fS. pneu-
moniae and 3 other potential pathogens (S. aureus, H.
influenzae and M. catarrhalis). Sixty-nine percent of the
children carried at least once S. pneumoniae. Number of
colonies per sample was not determined. Only one col-
ony of each bacterial species was included per sample.
Detailed information about the study was provided to
parents and school staffs. The Ethics Committee of the
Hôpital Universitaire des Enfants Reine Fabiola
approved the study. Signed informed consents were
obtained from parents.
Bacterial strains
A collection of 362 S. pneumoniae strains were isolated
from healthy children [30]. S. pneumoniae isolates were
identified by optochine-susceptibility test, bile solubility
Table 1 Utilization and adaptation of the original multiplex published by Pai and colleagues
Year Country Age Aim of the study Isolates Method No of
samples
Concordance * Nb
serotypes/
groups
Ref
Plating
2006 USA All develop and validate
the multiplex
IPD (blood) multiplex PCR 421 100% 29 [23]
2007 Mozambique < 15 years adapted to African
epidemiology
IPD (blood
+CSF)/AOM
multiplex PCR 153 91.50% 29 [21]
2007 Brazil < 5 years adapted to Latin
American
epidemiology
IPD (blood
+CSF)/
pleural fluid
multiplex PCR 147 94.60% 30 [25]
2010 Spain All adapted to European
epidemiology
IPD multiplex PCR 257 95.7% 29 [24]
No
plating
2008 Italy 0-14 years PCR-based serotyping
directly on clinical
specimens
IPD (blood
+CSF)/
pleural fluid
RT-PCR +
multiplex PCR
92 NA 31 [35]
2009 Gambia All detect multiple
carriage
carriage multiplex PCR 279 NA 29 [29]
2010 USA < 2 years detect multiple
carriage+low density
carriage Broth enrichment
+ RT-PCR +
multiplex PCR
100 NA 40 [28]
2008 Bangladesh ND PCR-based serotyping
directly on clinical
specimens
meningitis
(CSF
+isolates)
multiplex PCR on
isolates and
directly on CSF
358 NA 56 [26]
2010 Burkina Faso
and Togo
All PCR-based serotyping
directly on clinical
specimens
meningitis
(CSF
+isolates)
multiplex PCR on
isolates and
directly on CSF
194 NA 29 [27]
* between conventional and PCR-based serotyping. IPD Invasive Pneumococcal Disease; CSF Cerebrospinal Fluid; AOM Acute Otitis Media; ND Not Determined;
NA Not applicable (Studies use PCR to yield additional results compared to bacterial isolation and conventional serotyping, no concordance can be calculate
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[31].
S. pneumoniae typing
S. pneumoniae isolates were serotyped by Quellung
reaction performed by 2 different experimenters. Thirty-
three different serogroups/types were identified [30].
Thirty isolates were assigned as non-typeable pneumo-
cocci (NTP). These 30 isolates were excluded from this
study. The vast majority of these isolates did not show
any amplification for the cpsA internal positive control
(data not shown). A total of 332 isolates was therefore
included in this study. Serotypes of these isolates were
also determined using the original multiplex PCR assay
described in Pai and colleagues [23]. Additional primers
described in [25,26] as well as primers specific to sero-
type 6C [32], 23A, 23B and 35A (newly designed by the
CDC, (http://www.cdc.gov/ncidod/biotech/strep/pcr.
htm)) were tested. All the primers used in this study
have therefore been previously published (Table 2). Pri-
mers specific to the cpsA gene were used as an internal
positive control. This gene is part of the cps locus and is
highly conserved in pneumococci [23].
In case of non-concordant results, serotypes were
double-checked using the Quellung reaction and the
multiplex PCR assay. In case of non-concordance, the
national reference laboratory confirmed the Quellung
identification.
Molecular methods as DNA extraction, PCR and PCR
product detection on 2% agarose gel were performed as
described in [23]. Briefly, a bacterial suspension with a
turbidity of MacFarland standard 1 was boiled at 100°C
for 5 min and frozen at -20°C for 5 min. The PCR reac-
tions were performed in 25 μlw i t h2 . 0Uo ftaq DNA
polymerase (Promega Inc.), 5 μl of Promega green buffer
5X, 2.5 mM magnesium chloride, 200 μM of each
DNTP (Promega Inc.), 2.5 μl of bacterial crude extract
and primers with concentration as specified in Table 3.
PCR reactions were performed using a Biometra T3000
thermocycler using the following conditions: 4 min at
94°C followed by 30 cycles composed of 45s at 94°C,
45s at 54°C and 150s at 65°C.
Results
In silico design of the multiplex PCR assay
A novel multiplex PCR assay was developed for specific
detection of the 30 classical colonizing S. pneumoniae
serogroups/types (Table 3). This multiplex assay is com-
posed of 7 consecutive PCR reactions combining pri-
mers that have been already described in different
studies [23,25,26] (Table 3). Serotypes included in the 7
PCR reactions were chosen upon their prevalence in
carriage studies [7] to maximize serotypes determination
in a limited number of PCR reactions. Primers were
combined in each reaction to yield differences of more
than 70 bp in PCR fragment size for non-ambiguous
interpretation. Each PCR reaction includes a primer pair
specific to the cpsA gene as internal positive control.
The specificity of the selected primer pairs was
assessed in silico with the Primer-Blast software (http://
www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?
LINK_LOC=BlastHome) (default parameters with ‘nr’
database and ‘Streptococcus pneumoniae taxid’ species).
Table 2 shows that 18 primer pairs are predicted to be
specific to a given serotype (10A, 16F, 17F, 19A, 19F,
23A, 23B, 23F and 35B) or serogroup (1, 3, 4, 6, 14, 18,
22, 31 and 34) while the 12 others might present some
cross-reactivity between different serotypes (7A/F, 9A/V,
11A/D/F, 15A/F, 15B/C and 24A/F) or serogroup (7C/B
with 40; 12F with 12A/B, 44 and 46; 33F with 33A and
37; 35A with 35C and 42; 35F with 47F; 38 with 25A/F).
Some serotypes are only occasionally associated with
carriage and were therefore not included in the multi-
plex (e.g. serotypes 2, 5, 28, 29 and 46) [7].
Experimental validation of the multiplex PCR assay
The novel multiplex PCR assay was experimentally vali-
dated on a large and recent collection of S. pneumoniae
isolated from Belgian preschool healthy children at the
time of PCV7 adoption [30]. This collection included
332 typable isolates belonging to 31 serogroups/types
assigned by Quellung reaction. Three serotypes (13, 28,
29) were not included in our PCR scheme. The PCR
discriminates serotype 15A from serotypes 15B/C and
serotype 35F from 35A. In total, 329 of the isolates
(96%) belong to the 30 serotypes included in the PCR
scheme. The 7 PCR reactions were tested on every
isolate of this collection. During the experimental
validation, we did not observe any primer inhibition and
specific identification of each serotype was accurate
(Figure 1).
The first PCR reaction (PCR-1) includes primers
specific to serogroup/type 6, 23F, 11A and 23A. About
one third of our collection was serotyped after PCR-1
(116/329 isolates, 35.25%) (Figure 2). Serogroup 6 pri-
mers cannot discriminate 6A and 6B isolates because of
the high sequence similarity in the target gene (wciP).
On the other hand, the newly discovered and emerging
serotype 6C can be identified by PCR. We additionally
tested the 60 serogroup 6 isolates using 6C primers (Pri-
mers described in Table 2, PCR condition as described
in material and methods). Serotype 6C is recognized as
an emerging serotype following PCV7 adoption [33,34]
and represents currently the predominant serogroup 6
serotype recovered in diseases in the USA [32]. No 6C
isolates were present in our collection. The amplification
of the internal control (cpsA) was present for 115 of the
116 strains identified by PCR-1. cpsA control
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Name Sequences (5’ ® 3’) Amplicon size
1-f CTC TAT AGA ATG GAG TAT ATA AAC TAT GGT TA 280
1-r CCA AAG AAA ATA CTA ACA TTA TCA CAA TAT TGG C
3-f ATG GTG TGA TTT CTC CTA GAT TGG AAA GTA G 371
3-r CTT CTC CAA TTG CTT ACC AAG TGC AAT AAC G
4-f CTG TTA CTT GTT CTG GAC TCT CGA TAA TTG G 430
4-r GCC CAC TCC TGT TAA AAT CCT ACC CGC ATT G
6-f AAT TTG TAT TTT ATT CAT GCC TAT ATC TGG 250
6-f TTA GCG GAG ATA ATT TAA AAT GAT GAC TA
6C-f CAT TTT AGT GAA GTT GGC GGT GGA GTT 727
6C-r AGC TTC GAA GCC CAT ACT CTT CAA TTA
7C/B (40)-f CTA TCT CAG TCA TCT ATT GTT AAA GTT TAC GAC GGG A 260
7C/B (40)-r GAA CAT AGA TGT TGA GAC ATC TTT TGT AAT TTC
7A/F-f CCT ACG GGA GGA TAT AAA ATT ATT TTT GAG 826
7A/F-r CAA ATA CAC CAC TAT AGG CTG TTG AGA CTA AC
9A/V-f CTT CGT TAG TTA AAA TTC TAA ATT TTT CTA AG 753
9A/V-r GTC CCA ATA CCA GTC CTT GCA ACA CAA G
10A-f GGT GTA GAT TTA CCA TTA GTG TCG GCA GAC 628
10A-r GAA TTT CTT CTT TAA GAT TCG GAT ATT TCT C
11A/D/F-f GGA CAT GTT CAG GTG ATT TCC CAA TAT AGT G 463
11A/D/F-r GAT TAT GAG TGT AAT TTA TTC CAA CTT CTC CC
12F (12A/B, 44, 46)-f GCA ACA AAC GGC GTG AAA GTA GTT G 376
12F (12A/B, 44, 46)-r CAA GAT GAA TAT CAC TAC CAA TAA CAA AAC
14-f* GAA ATG TTA CTT GGC GCA GGT GTC AGA ATT 189
14-r* GCC AAT ACT TCT TAG TCT CTC AGA TGA AT
15A/F-f ATT AGT ACA GCT GCT GGA ATA TCT CTT C 434
15A/F-r GAT CTA GTG AAC GTA CTA TTC CAA AC
15B/C-f TTG GAA TTT TTT AAT TAG TGG CTT ACC TA 496
15B/C-r CAT CCG CTT ATT AAT TGA AGT AAT CTG AAC C
16F-f CTG TTC AGA TAG GCC ATT TAC AGC TTT AAA TC 988
16F-r CAT TCC TTT TGT ATA TAG TGC TAG TTC ATC C
17F-f TTC GTG ATG ATA ATT CCA ATG ATC AAA CAA GAG 693
17F-r GAT GTA ACA AAT TTG TAG CGA CTA AGG TCT GC
18-f CTT AAT AGC TCT CAT TAT TCT TTT TTT AAG CC 573
18-r TTA TCT GTA AAC CAT ATC AGC ATC TGA AAC
19A-f GTT AGT CCT GTT TTA GAT TTA TTT GGT GTT GT 478
19A-r GAG CAG TCA ATA AGA TGA GAC GAT TGT TAG
19F-f GTT AAG ATT GCT GAT CGA TTA ATT GAT ATC C 304
19F-r GTA ATA TGT CTT TAG GGC GTT TAT GGC GAT AG
22-f GAG TAT AGC CAG ATT ATG GCA GTT TTA TTG TC 643
22-r CTC CAG CAC TTG CGC TGG AAA CAA CAG ACA AC
23A-f*** TAT TCT AGC AAG TGA CGA AGA TGC G 722
23A-r*** CCA ACA TGC TTA AAA ACG CTG CTT TAC
23B-f** TTG TTA GTG GTA TTA AAT TGG GGA CTA CTA GG 216
23B-r** ATA CCT ATC TGA AGT GTT ATT AAC CCA CCA AC
23F-f GTA ACA GTT GCT GTA GAG GGA ATT GGC TTT TC 384
23F-r CAC AAC ACC TAA CAC TCG ATG GCT ATA TGA TTC
24A/F-f** TCT CAA CCA AGA TAC AGA TTT TGA TTT TAC TC 686
24A/F-r** TAT AAA CCT TTA GTA AAC ACT CTG CTT GAT CG
31-f GGA AGT TTT CAA GGA TAT GAT AGT GGT GGT GC 701
31-r CCG AAT AAT ATA TTC AAT ATA TTC CTA CTC
33F (33A/37)-f GAA GGC AAT CAA TGT GAT TGT GTC GCG 338
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23A specific amplicon of 723 bp was present). Twenty-
two serotype 23A and 29 serotype 23F pneumococci are
present in our collection. PCR-1 successfully identified
15 (68%) 23A and 22 (76%) 23F but no specific amplifi-
cation was observed for 7 serotype 23A (32%) and 7 ser-
otype 23F (24%). Subsequent testing of these strains
with specific antisera at the National reference labora-
tory for pneumococci confirmed serotype 23A and 23F
identification. The PCR identified accurately all other
serotypes included in PCR-1 (6 and 11A). In total,
PCR-1 successfully identified 116 (88%) of the 130 iso-
lates belonging to serotypes 6, 23F, 11A and 23A. The
experimental validation of the 4 primer pairs included
in PCR-1 was 100% specific as no false positive results
were obtained and no discrepancies with Quellung iden-
tification were observed. PCR - 1i d e n t i f i e d3 7s e r o g r o u p
23 pneumococci but could not assign a serotype to 14
serogroup 23 strains.
The second PCR reaction (PCR-2) is specific to sero-
types 23B, 19F, 19A and 38. This reaction assigned a
serotype to 69 isolates. After the 2 first reactions, more
than half of the isolates were typed (185/329; 56.23%).
cpsA internal control was missing for 9 out of 10 sero-
type 38 isolates but was present in every other isolate.
In comparison to the Quellung serotyping, PCR-2 pre-
sented 97% sensitivity and 100% specificity. Only 2 out
of 9 serotype 23B pneumococci (confirmed by the
National reference laboratory) did not present any speci-
fic amplification.
The third reaction, PCR-3, detects serotypes 1, 3, 15B/C
and 35B. This reaction allowed for serotype identifica-
tion of 61 isolates. After 3 reactions, 74.77% of our
Table 2 Multiplex primer (Continued)
33F (33A/37)-r CTT CAA AAT GAA GAT TAT AGT ACC CTT CTA C
34-f GCT TTT GTA AGA GGA GAT TAT TTT CAC CCA AC 408
34-r CAA TCC GAC TAA GTC TTC AGT AAA AAA CTT TAC
35A (35C/42)-f*** ATT ACG ACT CCT TAT GTG ACG CGC ATA 280
35A (35C/42)-r*** CCA ATC CCA AGA TAT ATG CAA CTA GGT T
35B-f GAT AAG TCT GTT GTG GAG ACT TAA AAA GAA TG 677
35B-r CTT TCC AGA TAA TTA CAG GTA TTC CTG AAG CAA G
35F (47F)-f GAA CAT AGT CGC TAT TGT ATT TTA TTT AAA GCA A 517
35F (47F)-r GAC TAG GAG CAT TAT TCC TAG AGC GAG TAA ACC
38 (25A/F)-f CGT TCT TTT ATC TCA CTG TAT AGT ATC TTT ATG 574
38 (25A/F)-r ATG TTT GAA TTA AAG CTA ACG TAA CAA TCC
cpsA-f GCA GTA CAG CAG TTT GTT GGA CTG ACC 160
cpsA-r GAA TAT TTT CAT TAT CAG TCC CAG TC
The majority of primer sequences are available on the CDC website (http://www.cdc.gov/ncidod/biotech/files/pcr-oligonucleotide-primers-March2010.pdf);
*, ** and *** indicate primer sequences published by [25,26], CDC website respectively. The name of each primer has been modified accordingly to the results
obtained with the primer blast software.
Table 3 Multiplex design
Primers Primer concentration (μM)
Reaction 1 6A/B/C 1
23F 1.5
11A 1.5
23A 2
Reaction 2 23B 0.75
19F 1
19A 1.5
38 1.5
Reaction 3 1 0.75
31
15B/C 1.25
35B 1.5
Reaction 4 14 0.75
34 0.75
22F 1.25
9A/V 1.5
Reaction 5 35A 0.75
12F 1
24A/F 1.25
16F 1.25
7A/F 2
Reaction 6 33F 1
41
35F 1.25
10A 1.5
31 1.5
Reaction 7 7B/C 0.75
15A 1
18C 1
17F 1.25
Primers cpsA-f and cpsA-r were included in all reactions at 0.5 μM each.
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with conventional serotyping (100% sensitivity and
specificity).
PCR-4 (including serotypes 14, 34, 22F, 9A/V), PCR-5
(35A, 12F, 24A/F, 16F, 7A/F), PCR-6 (33F, 4, 35F, 10A,
31) and PCR-7 (7B/C, 15A, 17F, 18) allowed for the
identification of 9%, 5%, 4% and 2% of the collection
respectively (cumulative frequencies presented in
Figure 2). The sensitivity and specificity were 100% for
the last 4 PCR reactions.
In total, PCR-deduced results were concordant with
conventional serotyping and allowed for the accurate
identification of 313 out of 329 pneumococci of our
collection (95.13%) (Figure 2).
Figure 1 Multiplex PCR reactions adapted to colonizing pneumococci. M means molecular size in bp.
Figure 2 Serotype coverage of the Multiplex PCR. Number of pneumococcal isolates and cumulative frequencies for each serotype. C%,
Cumulative Frequencies.
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PCR schemes were developed to detect IPD associated
serotypes distribution [21,23-26]. Different authors have
validated, adapted and improved the original multiplex
PCR assay developed by Pai and colleagues [23]. These
studies are summarized in table 1. The authors demon-
strated the specificity of primers for IPD isolates in Africa
[21], Asia [26], South-America [25] and Europe [24].
Moreover, PCR results were in agreement with conven-
tional serotyping (91 to 100%) and a new PCR scheme
was proposed for each location. The PCR multiplex assay
w a sa l s ou s e dt od e t e c tc a r r i age isolates in two studies
[28,29]. However, as serotypes associated with carriage
and with diseases differ, the proposed PCR schemes were
not optimal to rapidly serotype colonizing pneumococci.
We thus designed a multiplex PCR scheme specific to
carriage-associated serotypes. This assay can be used
worldwide since serotype distribution of colonizing iso-
lates is quite similar between different geographic loca-
tions. The most frequent serogroups are 6, 14, 19 and 23
[7]. Other colonizing serogroups frequently isolated from
children are 3, 4, 9, 11, 13, 15, 18 and 33 [7].
The multiplex assay requires little technical skills and
only basic PCR capabilities that are nowadays broadly
accessible. Moreover, colonizing pneumococci represent
a potent biological tool to monitor serotypes distribu-
tion and antimicrobial resistance level. Indeed, consider-
ing serotype prevalence in colonisation, rather than in
disease, may be more accurate, faster and cheaper to
evaluate pre- and post-vaccine product adoption [29].
The main disadvantage of PCR-based serotyping is the
incapacity to discriminate closely-related serotypes such
as 6A and 6B, 7F and 7A, 33F, 33A and 37, 35A, 35C
and 42 (Table 2) but this accounts mainly for minor ser-
otypes. Moreover, our in silico analysis of primer specifi-
city showed that some primer pairs are predicted to
present some cross-reactivity with other serogroups (e.g.
primer pair for 7C/B, 12F, 33F, 35A, 35F and 38). This
potential drawback could not be experimentally assessed
in our collection as several serogroups were lacking in
our collection. However, no false-positive result was
obtained. As a consequence, when an amplicon of the
proper size is obtained, isolates do not need to be tested
with the following PCR reactions, as described pre-
viously [23].
The present scheme successfully typed 95.1% of our
isolates belonging to serotypes included in the multiplex
assay. This corresponds to 94.3% of the whole collection
since primer pairs specific to 3 serotypes (13, 28 and 29,
corresponding to three isolates) are not present in our
assay. This validation confirms the flexibility of the mul-
tiplex PCR method because different primer pair combi-
nations can be used. Moreover our method is rapid as
75% of our isolates were assigned a serotype after only 3
PCR reactions. For colonizing pneumococci, 2 studies
evaluated the use of a PCR method to detect low coloni-
sation rate and multiple colonizing serotypes from naso-
pharyngeal samples [28,29]. This approach of direct
serotype determination, without bacterial plating and
isolation, is attractive but shows limitations such as
incapacity to determinate antibiotics resistance profile
or to apply complementary typing tools such as MLST.
Primers accurately identified the majority of ser-
ogroups/types included in our scheme but a lack of sen-
sitivity of primers specific to serogroup 23 was observed.
The sixteen strains for which no serotype could be
assigned by PCR are belonging to serogroup 23 and
represent 26.7% of the total serogroup 23 pneumococci
isolated in our study (16/60). The Belgian serogroup 23
colonizing pneumococci present most likely sequence
variability in the target gene (wzy for serotype 23A and
23F, wzx for serotype 23B) and are therefore not ampli-
fied by the current primer pairs. This demonstrates the
need to validate the PCR-based method in different
populations and locations to assess primers accuracy
and specificity within a given serotype. Moreover, iso-
lates that are non-typable by PCR should be monitored
with Quellung technique to assess for the emergence of
variants in pneumococcal serotypes.
In our collection, several pneumococci were assigned a
serotype by multiplex PCR but did not present a cpsA-
specific amplification (3%). This was already observed by
Carvalho and colleagues at a rate of 1 to 2% [28]. This
particularity is serotype dependent with serotype 38 and
25F generally negative for cpsA. We confirm this obser-
vation for colonizing serotype 38 (9 out of 10 isolates
were cpsA negative). Variation within a serotype, inca-
pacity to discriminate serotypes and occasional absence
of the internal positive control represent the major
weaknesses of the PCR-based method. These problems
will likely be overcome in the near future with increas-
ing sequencing of pneumococcal capsule locus.
Sequence comparisons will enable the identification of
conserved and specific sequences within a given sero-
type as well as the detection of conserved regions
through 93 serotypes to design a reliable positive con-
trol. This will undoubtedly improve the PCR-based
method.
Conclusions
To conclude, we have developed the first multiplex PCR
assay designed for colonizing pneumococci. In the pre-
sent study, we demonstrate that the PCR-based method
is a simple, robust and economical method for serotype
determination of colonizing pneumococci. We also
demonstrate the accuracy of primers for carriage isolates
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the Quellung reaction.
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